Sarcoma Highlights : ASCO 2021

With the pharma industry presenting abstracts, presentations and late-breakers highlighting their developments in the Sarcoma market, DelveInsight has charted out some of the most interesting ones out of all. Have a preview of the analysis and thoughts down below.

Abstract 11504_afamitresgene autoleucel_Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS)_Adaptimmune 

SPEARHEAD-1 trial: Most promising MAGE-A4 targeting T-Cell Therapy

Adaptimmune presented the preliminary data of the SPEARHEAD-1 Phase II trial that evaluated afamitresgene autoleucel in advanced/metastatic synovial sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS). It was analyzed that the T-cell therapy is safe and well-tolerated with mainly low grades of cytokine release syndrome. The overall response rate was found to be 41.1% in synovial sarcoma and 25% in MRCLS, with the disease control rate of 84.8%. Also, responses were observed in wide ranges of MAGE-A4 expression and cell doses. These results are encouraging, and based on the final results of this ongoing trial, the company is planning to file a BLA in 2022. Vast opportunities are awaiting for the Adaptimmune in various other MAGE-A4 expressing cancers.

Experts Views: “Compared to cytotoxic chemotherapy, afamitresgene autoleucel has shown durable responses and seems promising. Further follow-ups will reveal more insights on it.”


Abstract 11505_ AL3818 (Catequentinib, Anlotinib)_ Metastatic or Advanced Synovial Sarcoma_ Advenchen Laboratories 

APROMISS Trial: Superior results over dacarbazine in advanced Synovial Sarcoma

The Phase III trial results of AL3818 (Catequentinib, Anlotinib) show promising results with improved disease control, superior progression-free survival, and a slightly better safety profile over dacarbazine in advanced synovial sarcoma. Catequentinib has shown a median progression-free survival (mPFS) of 2.89 months compared to 1.64 months in patients treated with dacarbazine. With the significant mPFS, catequentinib has also shown a 67% reduction in the risk of disease progression.

Abstract 11557_ INT230_ advanced sarcomas_ Intensity Therapeutics Early efficacy signs of INT230-6 in Advance Sarcoma

Intensity Therapeutics has presented early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas. The novel therapy targets the limitation of systemic therapies such as low tumor penetration and severe adverse effects. The preliminary data shows that intratumoral INT230-6 was well-tolerated alone and in combination with ipilimumab. The disease control rate for the overall population at 50 days was 60%. The preliminary estimate of mOS was 21.3 months. These clinical benefits need to be further evaluated with more appropriate endpoints, i.e. overall survival and disease control rate. 


Abstract 11500_ TK216_ relapsed/refractory Ewing sarcoma_Oncternal Therapeutics

Promising safety and early antitumor activity of TK216 in combination with vincristine in R/R Ewing sarcoma

The first investigational drug, TK216, targeting ETS-family transcription factor oncoproteins, was found to be well-tolerated and has shown early signs of efficacy in heavily pretreated Ewing sarcoma. It has shown notable responses and a disease control rate of 45.2%. As per experts, it is a promising combination therapy for metastatic and relapsed Ewing sarcoma. TK216 has already received a rare pediatric disease designation, and that makes it eligible for priority review as well.

Despite the rarity of Sarcomas and challenges that come across during diagnosis, the Sarcoma market is witnessing a lot of activity, with several pharma players exploring novel therapeutic agents. DelveInsight has recently published covering several types of Sarcomas. Have a detailed view of report offerings and coverage here